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Food for Thought …
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Abstract

This year marks the 60 th anniversary of Russell and Burch’s pioneering book, The Principles of Humane Experimental
Technique. Their 3Rs framework has helped to inspire humane and scientific progress in experimental technique. However,
it is time to update its strategic application. The 21st century has already seen the development of promising, high-tech
non-animal models, such as organs-on-a-chip and computational approaches that, in our view, will replace animals as
the default option in biomedical experimentation. How fast this transition will take place will depend on the pace at which
these new models are optimized to reflect the biology of humans, rather than that of non-human animals. While the new
methods are likely to reshape all areas in which animals are currently used in science, we particularly encourage their
application in biomedical research, which accounts for the bulk of animals used. We call for the pursuit of a three-prong
strategy that focuses on (1) advancing non-animal methods as replacements of animal experiments, (2) applying them
to biomedical research, and (3) improving their relevance to human biology. As academics and scientists, we feel that
educational efforts targeted at young scientists in training will be an effective and sustainable way to advance this vision.
Our strategy may not promise an imminent end to the use of animals in science, but it will bring us closer to an era in which
the 3Rs are increasingly perceived as a solution to a receding problem. Russell and Burch themselves surely would have
welcomed these positive changes.

1 Introduction
The Principles of Humane Experimental Technique, the landmark
book that gave us the 3Rs framework of replacement, reduction,
and refinement, turns 60 this year. First published in 1959, Principles was the outcome of a project spearheaded by the Universities Federation for Animal Welfare (UFAW), overseen by a committee that included future Nobel Prize-winning scientist Peter
Medawar, and carried out by the British scientists William Russell and Rex Burch (Russell and Burch, 1959). The 3Rs framework helped to inspire and guide humane progress in experimental technique during the second half of the 20th century and beyond (Stephens and Mak, 2013; Balls et al., 2019).
The 60th anniversary of Principles falls in the midst of substantial developments in non-animal methods, i.e., potential replacement technology. Indeed, scientific experimentation is at
the cusp of a new era of techniques hardly imagined in the mid-
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20th century. Relevant techniques include (among others) organson-a-chip (microdevices containing cells and fluids intended to
simulate physiological processes in organs); organoids (three-dimensional spheroids containing multiple cell types and intended
to simulate physiological processes); high-throughput systems
(rapid screening of large numbers of chemicals for biological activity against panels of different cells or biomolecules); induced
pluripotent stem cells (adult cells that have been genetically reprogrammed to an embryonic stem cell-like state); and computational modeling (using computation to study the behavior of complex
systems).
In our view, these methods (and no doubt others in various
stages of development) have the potential to replace the use of
animals as the default option in both safety testing and biomedical research. That is, these methods will come to comprise the
rule, with animal experiments being the exception. This is consistent with Dutch efforts to expeditiously end animal experi-
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mentation in that country, primarily through vigorous development and application of alternative methods (Netherlands National Committee for the protection of animals used for scientific
purposes, 2016). The emphasis in the 21st century is likely to be
on expanding and exploring the capabilities of these non-animal
methods further and using them to better understand human biological pathways and the perturbations to these pathways that
can cause disease.
In this perspective paper, we take the anniversary of Principles
as an opportunity to reflect on these issues and comment on priorities that the 3Rs community and like-minded scientists should
consider adopting as we move forward. We briefly describe the
scale of animal use in science and comment on 21st century methods and approaches before introducing our overaching strategy
and concluding with remarks regarding Russell and Burch.

2 The global scale and nature of animal
experimentation
When Russell and Burch examined the “ecology of experimental
animals,” their focus was limited to Great Britain, where the government had long published fine-grained annual statistics on laboratory animal use. They estimated that almost 1.8 million vertebrates were used in 1955 (Table 4 in Russell and Burch, 1959).
This number has increased to 5.53 million animals (Home Office,
2018). Although the latter part of the 20th century saw a sizable
decline in animal use in Great Britain and elsewhere (De Greeve
et al., 2004), that trend reversed when the genetic modification of
animals became possible (Ormandy et al., 2009).
Only rough estimates exist for global animal use as many countries appear not to publish their animal use statistics. It was estimated that more than 127 million vertebrate animals were used
worldwide for scientific purposes in 2005 (Knight, 2008) and this
number has increased further since then (Taylor and Rego Alvarez, 2019). Novel, straightforward genetic modification techniques such as CRISPR will likely lead to a further increase in the
number of genetically modified animals being created, bred and
used, and also to genetic modifications of further species (Bailey,
2019).
In the European Union (EU), and perhaps elsewhere, basic and
applied research accounts for most of the animals used in science,
as indicated in the “Seventh report on the statistics on the number
of animals used for experimental and other scientific purposes”
released by the European Commission (EC, 2011). Other categories of use include production and quality control of devices and
products used in human medicine and dentistry, and toxicological and other safety tests, among others. Between 1995 and 2011,
about 65% of animals were used in basic and applied research by
the 15 EU Member States (at the time) plus Switzerland (Daneshian et al., 2015). In 2016, 47% of procedures were conducted
for basic research and 21% for applied research based on the national statistics of 26 reporting EU Member States (Taylor and
Rego Alvarez, 2019). Directive 2010/63/EU (EU, 2010) has put
in place a more comprehensive reporting framework for Member
States; as a result, more precise estimates of animal use in the EU
will be available in the next overall report due in late 2019.
344

The high numbers of animals used in biomedical research
warrant additional emphasis to replace their use in these fields.
Although toxicity testing accounts for less than 10% of animal
use in science, much of the attention of the 3Rs to date has been
focused on this area (Stephens and Mak, 2013). The reasons for
this include the limited number of targets for replacement in this
field, public concern over this type of animal testing, and the possibility to gain government approval for developed replacement
tests. In contrast, biomedical research is a far more diverse and
decentralized area, where, in principle, originality and innovation
are most highly prized. Thus, this field presents a different set of
challenges to replacement advocates. However, the new non-animal methods offer human-relevant insights and diverse high-tech
research opportunities, which can be adapted to specific research
needs. Importantly, changing to non-animal methods in this field
is a matter of choice based on knowledge as well as on funding,
but it is not determined by regulatory requirements.

3 The expanding toolbox of non-animal methods
and approaches
In their chapter on replacement, Russell and Burch (1959) noted that “(m)ammalian tissue cultures … have become, since the
Second World War, one of the most important replacing techniques, and indeed one of the most important developments in
biology” (p. 72). This development was facilitated by the discovery of antibiotics, which suppress the growth of bacteria that often contaminate cell cultures. During the balance of the twentieth century, tissue culture began to be applied in a wide array of
fields. However, this technique was largely limited to homogenous, two-dimensional arrays, short-lived in vitro preparations,
and relatively crude reconstructed tissue.
Today, the in vitro/cell culture toolbox is much more sophisticated and diverse. It includes organ-on-a-chip microphysiological systems (Andersen et al., 2014; Marx et al., 2016); three-dimensional organoids containing multiple cell types; robot-assisted, high-throughput systems (van Vliet et al., 2014); high-content
imaging technologies; and DNA or RNA microarray screening.
Also available are computational tools and approaches, machine
learning and artificial intelligence (AI) to help make sense of “big
data” (Hartung and Hoffman, 2009; Hartung, 2016, 2018; Luechtefeld et al., 2018).
These methods have a number of advantages over 20th century in vitro approaches, which can include speed, throughput, and
biological relevance. Multiple cell types, 3D architecture, fluid
exchange, etc. enable the models to function more like human
tissues or organs and to survive in culture for longer time periods.
Owing to the development of induced pluripotent stem cells, the
models can now be seeded with non-cancerous, differentiated human cells and, thanks to microphysiological systems technology,
different “organs” can be connected with one other.
Much has already been written about these and other 21st century tools and approaches (Langley et al., 2017; Noor, 2019;
Wilkinson, 2019; Benam et al., 2019; Bowman et al., 2018; Savoji et al., 2019; Marshall and Willett, 2018; Marshall et al., 2018;
Boeckmans et al., 2018; Pistollato et al., 2016; Langley et al.,
ALTEX 36(3), 2019

Herrmann et al.

2015). Here we would like to mention several recent developments that have been key in driving non-animal methods forward: The U.S. National Research Council report on “Toxicity Testing in the 21st Century: A Vision and a Strategy” (NRC,
2007) and the EU legislation governing animal experimentation
(Directive 2010/63/EU on the protection of animals used for
scientific purposes) (EU, 2010; Hartung, 2010) created a more
welcoming environment for the new methods and officially
recognized their potential to replace animal use. Many of these
tools and approaches are now commercially available, which
has greatly increased their accessibility and diminished practical barriers to their adoption and use. Although high-throughput
testing is limited to centralized laboratories owing to the sophisticated equipment required for these arrays, median-throughput
versions of these assays are now more widely accessible. Also,
the focus has shifted away from 1:1 replacement of animal models to developing models with human relevance, thus enhancing
their translational value and their acceptance in the larger scientific community. “Human-on-a-chip” efforts have begun to interconnect numerous organ models in microphysiological arrays to
approach the complexity of the human body and be able to identify organs affected by chemical substances (Marx et al., 2012).
The development of these models and approaches has been facilitated by advances in stem cell technology, microengineering, microfluidics, computing power, and respective multidisciplinary cooperation.

4 A proposal to prioritize the 3Rs of replacement,
research, and (human-) relevance
Not surprisingly, sixty years after Russell and Burch proposed
the 3Rs, the landscape of animal experimentation and alternatives-related technology has changed. Despite successes in developing non-animal methods, especially for toxicological testing,
the scale of animal use in Great Britain – home of UFAW, Russell
and Burch, and the 3Rs – has more than tripled (Home Office,
2018). What must the 3Rs community change to become more
effective?
We propose a strategic focus that prioritizes: (1) replacement
over refinement and reduction, (2) biomedical research over safety testing, and (3) relevance to humans rather than to non-human
animals. One can think of these priorities as a new set of 3Rs
(replacement, research, and relevance) for the current era. These
three priorities are discussed in the following subsections.
An alternatives strategy that emphasized two of the three pillars highlighted here, namely replacement over reduction and refinement, and biomedical research over safety testing has been
proposed previously (Stephens, 2012). However, the importance
of our third pillar – human relevance – has been underscored by
recent attention to the reproducibility and translatability pitfalls
surrounding animal experiments and by the power of the new an-

imal-free methods to address human relevance in the years since
then.

4.1 Prioritizing replacement
In some respects, prioritizing replacement in the era of 21st century technology is simply an extension of Russell and Burch’s
thinking that reduction and refinement are interim steps on the
path towards replacement. They wrote:
“… refinement is never enough, and we should always
seek further for reduction and if possible replacement.
Still more generally, replacement is always a satisfactory
answer….” (p. 66) (Russell and Burch, 1959).
The motivating issue for them was the distress that animals could
experience in the laboratory. They referred to this as “inhumanity,” a term they sought to apply objectively without implying
any ethical judgement of the experimenters or staff. “Direct inhumanity” could result from the “unavoidable consequence of the
procedure employed,” no matter how well refined. In addition,
“contingent inhumanity” could result as an “incidental and inadvertent by-product of the use of the procedure, which is not
necessary for its success” (p. 54). In their view, it was better to
avoid both types of inhumanity by using replacement methods,
when available.
Prioritizing replacement in the 1950s was more quixotic than
practical. This was perhaps one reason for the delayed uptake of
the 3Rs framework during the 1960s and 1970s (Stephens and
Mak, 2013). Today, however, while much progress has been
made with reduction and refinement, the replacement toolkit is
more impressive and promising than ever. The new methods do
not necessarily translate into direct replacements of individual
animal models; combinations of methods may be needed to replace an animal model as an in vitro system is often still far less
complex than an organism. However, suitability to answer a research question depends on whether a model or model combination includes all relevant aspects of a (human) biological system,
not whether it models an organism in its entirety.
There are also societal reasons to favor replacement. A shift in
focus to animal-free methods would be in line with increasing international public concerns about laboratory animal suffering as
shown by the Stop Vivisection initiative in the European Union1
and recent Ipsos MORI studies conducted by research centers
such as Pew 2,3 and Gallup (Clemence and Leaman, 2016; Jones,
2017). In addition, the EU legislation governing animal experimentation not only calls for the use of non-animal methods,
where available (EC, 2010) (Recital 11), but has as its long-term
goal the phasing out of all animal use (EU, 2010, Recital 10). One
might call this “full replacement” (Stephens, 2012).
In the light of insurmountable species differences (Pound and
Ritskes-Hoitinga, 2018) and new possibilities offered by the novel technologies and approaches that are human-biology based, we
can and should put the most effort into replacing animal experiments with non-animal methods. Setting a priority means empha-

1 http://ec.europa.eu/citizens-initiative/public/initiatives/successful/details/2012/000007; http://stopvivisection.eu/en/content/why-stop-vivisection
2 http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/pi_2015-01-29_science-and-society-03-05/
3 http://www.pewresearch.org/fact-tank/2018/08/16/americans-are-divided-over-the-use-of-animals-in-scientific-research/
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Fig. 1: Schematic view of how human-based models/tools, technological approaches and readouts can be applied in biomedical
research to promote a systems biological understanding of disease etiopathology
Optogenetics involves the use of light to monitor cells in living tissue (typically neurons) that have been genetically modified to express
light-sensitive ion channels. Abbreviations: CSF, cerebrospinal fluid; GEP, gene expression profiling; GWAS, genome wide association
study; HCI, high content imaging; IC, immunocytochemistry; IH, immunohistochemistry; iPSC, induced pluripotent stem cells; MEA, multielectrode array; MRI, magnetic resonance imaging; PET, positron emission tomography

sizing some things over others. Issues that are no longer a priority
are de-emphasized, not necessarily abandoned. Thus, for a funding agency, prioritizing replacement could mean that more than
an equal share of funds go to this topic, while some funds are
nonetheless allocated to reduction and refinement.

4.2 Prioritizing biomedical research as the target
of non-animal methods
The major goals of biomedical research are the advancement of
human health, the discovery of effective and safe treatments for
humans, and the elucidation of the role of genetic and environmental risk factors in the onset and the consolidation of human
diseases. But although there is a globally recognized need to replace animal use in toxicology and regulatory testing whenever
possible (Balls, 2007; Hartung, 2009; Stephens and Mak, 2013),
this is not yet the case in basic and applied research, where most
of the animals are used (Daneshian et al., 2015; EC, 2011). Consequently, the value of animal models for biomedial research
should be critically appraised by means of systematic reviews,
meta-analyses, and citation analyses (e.g., Carvalho et al., 2019;
Hartung, 2013; Herrmann, 2019a; Knight, 2019; Pound et al.,
2004). Also, with regards to research funding strategies and prioritization, assessing return on investment with meaningful indicators is key to enable an assessment of the impact that publicly
346

funded animal-based research has had on citizens’ health, so as to
reassess how to channel funding more effectively to achieve the
goals of biomedical research.
Some of the approaches (if not the tools) used in toxicology
and regulatory testing could be applicable to biomedical research
(Gruber and Hartung, 2004). For instance, adverse outcome pathways (AOPs) are constructed to portray existing knowledge regarding the adverse effects elicited by chemicals in an agnostic
manner. AOPs identify the molecular initiating event and intermediate mechanisms (key events) underlying these effects up to
an adverse health outcome, and span multiple levels of biological complexity (i.e., population, organism, organ, cell, and genetic
levels). While AOPs have been conceived in the field of toxicology, their use would also be applicable to biomedical research, as a
more explicit framework for mechanistic studies. For example, by
using an AOP conceptual framework it could be possible to gather
existing knowledge about signaling pathways that are perturbed at
the onset and during the consolidation of a certain disease, and to
link genetic determinants, lifestyle and environmental factors with
adverse health effects (Langley, 2014; Pistollato et al., 2015).
An initiative aiming to further a human-focused, pathway-based
approach to studying, preventing and treating disease is the
BioMed 21 (Biomedical Research for the 21st Century) Collaboration, which is working internationally with health experts, regulaALTEX 36(3), 2019
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tory and research agencies, and funding bodies to develop innovative research roadmaps that focus on understanding human disease
pathophysiology.4 BioMed 21 envisions a “human-based pathway
approach to human disease research” applicable to a broad range
of human pathologies (Langley et al., 2017). The Collaboration
aims to use technological tools and biological models within an
AOP framework to study human pathologies, thereby promoting
the discovery of drug targets, and possibly reducing late-stage drug
attrition. Information is drawn from observational, prospective,
epidemiological, and interventional studies conducted in human
patient cohorts. The Collaboration also promotes global efforts to
improve transparency, increase reproducibility, and confirm associations described in epidemiological studies (Wang et al., 2016).
Complex cell models, such as human induced pluripotent stem
cells (hiPSCs) and their differentiated derivatives obtained from
patients and healthy subjects, are suitable for adaptation for biomedical research to replace animal experiments. These models
can be cultured in 3D to improve the level of physiological complexity, e.g., as organoids in microfluidic devices (Alépée et al.,
2014; Park et al., 2015; Skardal et al., 2016). Stem cell discovery
platforms are already yielding the first clinical candidates (Mullard, 2015; McNeish et al., 2015).
Proteins associated with signaling pathways and genetic/epigenetic factors can be studied with a wide array of omics technologies, next-generation sequencing approaches, and gene expression profiling; these, together with integrated computer modelling,
are already paving the way for a systems-biological understanding
of disease etiopathology (Fig. 1) without the use of non-human
animals and thus the problem of interspecies differences.
Tools that are suitable to address population/organism biological complexity include human ex vivo material derived from
healthy subjects and patients, such as blood and plasma samples,
cerebrospinal fluid, post-surgical biopsies, and post-mortem tissues, which can be useful to identify early biomarkers of human
diseases. Advanced imaging technologies such as imaging connectomics, which allows comprehensively mapping the neural elements and inter-connections constituting the brain, are providing
new insights into brain diseases (Fornito and Bullmore, 2015).
Such imaging data can be associated with cognitive test scores
and omics data, allowing multi-scale data integration (Fig. 1).

4.3 Promoting human relevance in biomedical
research
Prioritizing animal-free methods of high human relevance avoids
the limited translational value of animal models to human biology. Russell and Burch were keenly aware of the importance of
relevance in research, whether the research was aimed at understanding humans or another species. They distinguished between
models that had high fidelity versus high discrimination. The
former were grossly similar to what was being modeled (fidelity) but did not necessarily do a good job of predicting outcomes
when the experimental parameter was varied (discrimination).

Thus, the “high-fidelity fallacy” is the unfounded belief that, say,
a mouse would be a good predictor of the human situation in a
given context because both mice and humans are mammals. In
contrast, an in vitro system lacks fidelity to a human situation but
can nonetheless allow good discrimination, say, of which chemicals might cause skin sensitization in humans if it contains the
relevant cell types that are involved in the human skin sensitization process.
Clearly, the issues of model fidelity and discrimination described in the 1950s are still relevant today. High discrimination
yields high translatability, whereas the same cannot necessarily
be said of high fidelity. The decades since the 1950s have given
us ample evidence of the limited translatability of animal models to the human situation (e.g., Kramer and Greek, 2018; Pippin,
2012). For example, the overall likelihood of approval of a potential drug from preclinical studies, which are based largely on animal studies, is less than 10% (Hartung, 2013; Thomas et al., 2016;
Meigs et al., 2018) with efficacy and safety issues accounting for
the majority of failures (Harrison, 2016). In light of this, the relevance and reliability of animals for preclinical drug development
have been questioned5 (e.g., Kramer and Greek, 2018; Pound and
Bracken, 2014; Pound and Ritskes-Hoitinga, 2018; van der Worp
et al., 2010). Current NIH director Francis Collins, in an article
discussing the translation of basic biomedical science into safe
and effective clinical applications, also expressed significant reservations about animal models, stating that “the use of small and
large animals to predict safety in humans is a long-standing but
not always reliable practice in translational science” (Collins,
2011).
Some projects are still seeking to develop better animal models of diseases, e.g., the NIH-funded MODEL-AD consortium6
is engineering mice with different genetic mutations linked with
early- or late-onset Alzheimer’s. However, other scientists urge
caution: Bart de Strooper, a molecular biologist at the Catholic
University of Leuven (KU Leuven) declared that “the biggest
mistake you can make is to think you can ever have a mouse with
Alzheimer’s disease” (Reardon, 2018). Investing large amounts
of money, energy and time into the ‘remaking’ or optimizing animal models (animal models 2.0) has not mitigated the translational failure (Sutherland et al., 2012; Leung et al., 2018). However,
interviews with the animal research community on the causes of
the low reproducibility and translatability of animal experiments
showed no acknowledgement of limitations to extrapolating results from animals to humans (Fitzpatrick et al., 2018). A recent
survey (Franco et al., 2018) amongst participants of laboratory
animal science courses in four European countries (Denmark,
Germany, Switzerland, and Portugal) revealed that animal experimenters considered refinement more important and more achievable than replacement. In addition, they prioritized refinement
over reduction efforts, which is a reversal of the hierarchy postulated by Russell and Burch (Russell and Burch, 1959), who put
replacement first and refinement last.

4 http://biomed21.org/

5 https://www.the-scientist.com/news-analysis/more-compounds-failing-phase-i-49707
6 https://model-ad.org/
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Both the United States National Research Council report “Toxicity Testing in the 21st Century: A Vision and a Strategy” (NRC,
2007) and Directive 2010/63/EU (EU, 2010) recognize the need
to modernize toxicity testing and advocate an approach that emphasizes non-animal methods. Both documents highlight the
need to improve human relevance, foster a paradigm shift from
nearly exclusive reliance on animal experimentation to more human-based approaches, and introduce pathway-based approaches
to gather a mechanistic understanding of disease etiology. These
arguments are also applicable to biomedical research. Calls are
becoming louder for a shift towards methods that are human biology-based and, hence, human-relevant, to avoid the inaccuracy
in predicting efficacy and safety of drugs using current preclinical animal models (Archibald et al., 2018; Herrmann and Jayne,
2019; Kramer and Greek, 2018).
21st century methods allow scientists to incorporate human relevance as a primary design criterion of biomedical research models. In lung models, for example, relevant human cell types can
be incorporated into a lung-on-a-chip, with mechanical forces
mimicking the shear forces exerted during breathing (Huh et al.,
2010; Benam et al., 2017). Human samples, large data repositories, and computational and imaging tools are also available to
carry out human-relevant biomedical research.
Of course, no model is without its limitations; thus, 21st century
in vitro systems also have limitations, such as lacking the integration and longevity of an intact organism. They are designed
with the intention to simulate human biology up to a certain level
of organization and complexity, and each system’s relevance to
study a certain scientific problem must be carefully considered
and verified. Also, they must be performed by trained scientists
and follow best practice guidance to ensure quality results.
It should also be mentioned that microdosing has been recently considered a promising way to assess, by means of positron
emission tomography (PET) and accelerator mass spectrometry (AMS), pharmacokinetics and pharmacodynamics of tested
drugs administered at non-pharmacological doses to humans.
This facilitates exploratory studies directly in humans, while reducing the use of animals in preclinical toxicology (Bergstrom,
2017). The use of microdosing has been encouraged by regulatory agencies both in Europe and the United States, and a microdosing regulatory framework has been accepted by the International
Conference on Harmonization (ICH, 2009).
The failures in drug development may be related not only to
the use of animal models of questionable relevance to humans,
but also to the use of these models in a hyper-reductionist approach to dissect the possible contributions of single gene(s) or
protein(s) to the onset of complex, multi-factorial human pathologies. Some key issues should therefore be considered, in order
to refocus current and future research strategies and priorities in
biomedical research, as has already been advocated for Alzhei-

mer’s disease research (Pistollato et al., 2016). Human-based
methods should be used to elucidate disease processes at multiple levels of biological complexity (Fig. 1), such as by associating novel human-based cellular and computational models
with non-invasive imaging tools and epidemiological and clinical
data to facilitate human-relevant data discovery. In this regard,
some recent European initiatives are embracing a multidimensional and multidisciplinary perspective for the study of complex
brain interactions and Alzheimer’s disease research (Vaudano et
al., 2015). These initiatives include the Human Brain Project7
and the Innovative Medicines Initiative (IMI) with three complementary projects: the European Medical Information Framework (EMIF),8 the Aetionomy project (organizing mechanistic
knowledge about the biological pathways involved in the aetiology of neurodegenerative diseases, to guide the classification of
disease classes and subclasses)9 and EPAD (European Prevention
of Alzheimer’s Dementia Consortium).10 Similarly, in the United
States, the Accelerating Medicines Partnership (AMP) is aiming
to develop new diagnostics and treatments for Alzheimer’s disease, type 2 diabetes, autoimmune disorders (i.e., rheumatoid arthritis and systemic lupus erythematosus), and more recently also
Parkinson’s disease, by jointly identifying and validating new biological disease targets. The AMP is a public-private partnership
between the National Institutes of Health (NIH), the US Food and
Drug Administration (FDA), 12 biopharmaceutical and life science companies and 13 non-profit organizations.11 Similar transdisciplinary initiatives are ongoing in other biomedical research
areas and in other countries.

5 Increasing awareness, dissemination and
education on non-animal approaches
We recognize that advancing human-relevant, animal-free approaches in biomedical research should be a multi-faceted effort involving, inter alia, funding targeted at laboratory research,
graduate and post-doctoral research fellowships, and alternatives
prizes. However, a key step in transforming the current animal
use paradigm is increasing the awareness of currently available
animal-free methods. Without knowledge of these methods, scientists cannot adopt them, funding agencies cannot create programs to fund them, ethical review committees cannot ask why
they are not employed in a given protocol, and so forth. Consequently, knowledge-sharing through education and training plays
a central role in achieving the move away from animal experiments and towards human-biology based research methodologies
(Daneshian et al., 2011; Hartung et al., 2009; Herrmann, 2019a;
Holley et al., 2016). Here we address the narrow but far-reaching issue of educating future and early-career scientists on these
issues.

7 https://www.humanbrainproject.eu/en/
8 http://www.emif.eu/

9 https://www.aetionomy.eu/en/vision.html
10 http://ep-ad.org/

11 https://www.nih.gov/research-training/accelerating-medicines-partnership-amp
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In Europe, the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the Joint Research Centre (JRC)
has recently coordinated a study to review available education
and training resources that support the 3Rs approach.12 The aim
of this study is “to identify courses, modules, teaching materials,
guidance, and other resources to form a snapshot view of how,
where and to whom the 3Rs principles and alternative-to-animal
approaches are currently being taught keeping in mind that many such initiatives might not be ‘3R labelled’”. In the JRC report “Accelerating progress in the Replacement, Reduction and
Refinement of animal testing through better knowledge sharing”
(Holley et al., 2016), it is acknowledged that, although there are
many available 3Rs relevant knowledge sources, their impact
could be increased by, e.g., (i) increasing awareness and coordination, and (ii) better curating existing knowledge sources.
EURL ECVAM is currently collaborating with Directorate General Environment (DG ENV) on an initiative in which 3Rs experts design and produce eLearning modules for students and
professionals involved in laboratory animal use. The modules
cover the educational and training requirements under Directive
2010/63/EU with special focus on replacement methods to acclerate and aid the uptake of animal-free approaches in science.13
There are currently only a few courses available at the university level that are specifically teaching the 3Rs (Holley et al.,
2016). In the following we give a few examples of such courses.
One is run by one of the authors (KH) at Johns Hopkins University as part of the educational program offered by the Center for Alternatives to Animal Testing (CAAT). It is an 8-week course open
to graduate and undergraduate students consisting of 18 lectures
by and 10 interviews with international experts in their respective
fields, and it is complemented by virtual tours through two laboratories that use animal-free methods. The modules cover how
to fully apply the 3Rs principles and discuss the limitations of
animal use in science. Other topics include how to plan, conduct,
analyze and report research studies, as well as how to properly
formulate a research question, to conduct comprehensive literature searches, and to critically appraise the validity of animal
and non-animal models and methods in order to choose the best
means for particular research questions (Herrmann, 2019b). This
course will be complemented in the next academic year by courses focusing on non-animal approaches in basic and applied research, the ethics of animal use in science, and best practice approaches to reduce animal suffering and improve scientific rigor.
CAAT also offers classes on Toxicology in the 21st Century and
Evidence-based Toxicology. Toxicology in the 21st Century addresses the current paradigm change in regulatory toxicology, the
shortcomings of the current system, and the adaptation of novel
technologies to overcome them. The course Evidence-based Toxicology familiarizes students with the concepts of evidence-based

medicine and its translation to toxicology. Concepts of systematic
reviews, meta-analysis, risk-of-bias, and various quality assurance schemes are introduced. Both courses are offered for free
since 2018 on the online learning platform Coursera and had registered about 2500 active learners by June 2019.
To reach early career scientists, the JRC organized a Summer
School on “Non-animal Approaches in Science” in 2017 and
201914 to share knowledge and expertise on the newest innovative animal-free methods in research and testing and to discuss
the place of the 3Rs in science today. A further summer school is
planned for 2020 in the US.
The University of British Columbia (UBC) will be starting a
course on non-animal methods in biomedical sciences.15 Also,
the Canadian Centre for Alternatives to Animal Methods16 and
the Canadian Centre for the Validation of Alternative Methods17
(University of Windsor) have been developing academic programs in animal replacement science. At the undergraduate level,
they plan to offer a minor and a certificate program for science
majors, with the intention of developing a major degree program
over time. At the graduate level, they are currently developing a
one-year Master’s program on alternatives research – from science to ethics and hands-on training in alternative test methods
– and training doctoral students in their multidisciplinary human
biology-based research laboratory.18
We hope that targeted courses such as these will be adopted
into the curricula of many additional universities internationally
to inform future and early-career scientists on state-of-the-art 21st
century non-animal methods sustainably.

6 Conclusions
We believe that 3Rs advocates should consider what set of priorities (informed by the 3Rs) is most appropriate to their era and is
most likely to maximize return on investment. In 2019, we propose a strategy based on prioritizing Replacement, (biomedical)
Research, and (human) Relevance. These three Rs are not intended to replace the original set, but to represent a strategic application of Russell and Burch’s framework to an era ripe with non-animal methods, with opportunities to apply them in biomedical
research, and with ways to craft these methods to reflect human biology. To achieve this, we embrace a fresh perspective on the way
biomedical research is taught, planned and funded. Human-based
models and methods, including complex in vitro systems, in silico
tools and high-throughput approaches are now far developed and
should be pursued in a multidisciplinary and collaborative effort
to increase human relevance, reproducibility and, ideally, translatability of scientific data, as already envisioned in the last decades
in toxicology and regulatory testing (Gibson, 2010).

12 https://ec.europa.eu/jrc/en/science-update/education-and-training-3rs

13 https://ec.europa.eu/jrc/en/science-update/calls-experts-training-tools-alternatives-animal-testing

14 https://ec.europa.eu/jrc/en/event/conference/jrc-summer-school-non-animal-approaches-science

15 Personal communication with Dr. Elisabeth Ormandy, Executive Director, Animals in Science Policy Institute and Lecturer, University of British Columbia.
16 http://www.uwindsor.ca/ccaam/

17 http://www.uwindsor.ca/ccaam/303/canadian-centre-validation-alternative-methods-cacvam

18 Personal communication with Dr. Charu Chandrasekera, Executive Director, Canadian Centre for Alternatives to Animal Methods.
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We direct our proposal to scientists, advocates, funders and
institutions who are interested in non-animal methods and approaches. These are the players who are motivated to accelerate
progress, including through their own research, teaching, lobbying, allocation of funds, and the like.
Where does that leave Russell and Burch’s analysis and the
3Rs framework in the 21st century? To a certain extent, all of the
3Rs will retain some importance as long as any animals are used
in experimentation. However, if animal experiments are eventually no longer the norm, there will inevitably be less emphasis
on reducing and refining the remaining animal experiments (as
important as these activities still are now). Hence our call to focus
energies on optimizing and implementing replacement (non-animal) methods.
Our aim is not to diminish the legacy of Russell and Burch but
to mark the proper place of the 3Rs and to move forward towards
a new era in the history of humane experimental technique.

References

Alépée, N., Bahinski, A., Daneshian, M. et al. (2014). t4 workshop
report: State-of-the-art of 3D cultures (organs-on-a-chip) in safety
testing and pathophysiology. ALTEX 31, 441-477. doi:10.14573/
altex1406111
Andersen, M. E., Betts, K., Dragan, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools – Challenges and opportunities. ALTEX 31, 364-367. doi:10.14573/altex.
1405151
Archibald, K., Tsaioun, K., Kenna, J. G. et al. (2018). Better science
for safer medicines: The human imperative. J R Soc Med,
141076818812783. doi:10.1177/0141076818812783
Bailey, J. (2019). Genetic modification of animals: Scientific and ethical issues. In K. Herrmann and K. Jayne (eds.), Animal Experimentation: Working Towards a Paradigm Change (443-479). Vol. 22.
Leiden, The Netherlands: Brill. doi:10.1163/9789004391192_020
Balls, M. (2007). Alternatives to animal experiments: Time to focus
on replacement. AATEX 12, 145-154.
Balls, M., Combes, R. and Worth, A. (2019). The History of Alternative Test Methods in Toxicology. Academic Press. https://bit.ly/
2xHlyZq
Benam, K. H., Mazur, M., Choe, Y. et al. (2017). Human lung small
airway-on-a-chip protocol. Methods Mol Biol 1612, 345-365.
doi:10.1007/978-1-4939-7021-6_25
Benam, K. H., Gilchrist, S., Kleensang, A. et al. (2019). Exploring
new technologies in biomedical research. Drug Discov Today 24,
1242-1247. doi:10.1016/j.drudis.2019.04.001
Bergstrom, M. (2017). The use of microdosing in the development of
small organic and protein therapeutics. J Nucl Med 58, 1188-1195.
doi:10.2967/jnumed.116.188037
Boeckmans, J., Natale, A., Buyl, K. et al. (2018). Human-based systems: Mechanistic nash modelling just around the corner? Pharmacol Res 134, 257-267. doi:10.1016/j.phrs.2018.06.029
Bowman, P., Flanagan, S. E. and Hattersley, A. T. (2018). Future
roadmaps for precision medicine applied to diabetes: Rising to
the challenge of heterogeneity. J Diabetes Res 2018, 3061620.
doi:10.1155/2018/3061620

350

Carvalho, C., Alves, D., Knight, A. et al. (2019). Is animal-based
biomedical research being used in its original context? In K.
Herrmann and K. Jayne (eds.), Animal Experimentation: Working Towards a Paradigm Change (376-390). Vol. 22. Leiden, The
Netherlands: Brill. doi:10.1163/9789004391192_017
Clemence, M. and Leaman, J. (2016). Public attitudes to animal research in 2016. Ipsos MORI. https://www.ipsos.com/sites/default/
files/publication/1970-01/sri-public-attitudes-to-animal-research2016.pdf
Collins, F. S. (2011). Reengineering translational science: The time
is right. Sci Transl Med 3, 90cm17. doi:10.1126/scitranslmed.
3002747
Daneshian, M., Akbarsha, M. A., Blaauboer, B. et al. (2011). A
framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation.
ALTEX 28, 341-352. doi:10.14573/altex.2011.4.341
Daneshian, M., Busquet, F., Hartung, T. et al. (2015). Animal use for
science in europe. ALTEX 32, 261-274. doi:10.14573/altex.1509081
De Greeve, P., De Leeuw, W. and van Zutphen, B. (2004). Trends in
animal use and animal alternatives. Altern Lab Anim 32, Suppl 1A,
13-19. doi:10.1177/026119290403201s06
EC – European Commission (2011). Seventh report on the statistics
on the number of animals used for experimental and other scientific
purposes in the member states of the european union. 52013DC0859.
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:
52013DC0859
EU – European Union (2010). Directive 2010/63/EU of the European
Parliament and of the Council of 22 September 2010 on the protection
of animals used for scientific purposes. OJ L 276, 33-79. http://
eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:
32010L0063&from=EN
Fitzpatrick, B. G., Koustova, E. and Wang, Y. (2018). Getting personal
with the “reproducibility crisis”: Interviews in the animal research
community. Lab Anim (NY) 47, 175-177. doi:10.1038/s41684018-0088-6
Fornito, A. and Bullmore, E. T. (2015). Connectomics: A new paradigm
for understanding brain disease. Eur Neuropsychopharmacol 25,
733-748. doi:10.1016/j.euroneuro.2014.02.011
Franco, N. H., Sandoe, P. and Olsson, I. A. S. (2018). Researchers’ attitudes to the 3Rs – An upturned hierarchy? PLoS One 13,
e0200895. doi:10.1371/journal.pone.0200895
Gibson, J. E. (2010). An integrated summary of commentary on the
national academy of sciences report on “toxicity testing in the 21st
century: A vision and a strategy”. Hum Exp Toxicol 29, 33-35.
doi:10.1177/0960327109354659
Gruber, F. P. and Hartung, T. (2004). Alternatives to animal experimentation in basic research. ALTEX 21, Suppl 1, 3-31. http://www.
altex.ch/resources/altex_2004_Supp1_003_031_Gruber.pdf
Hartung, T. (2009). Toxicology for the twenty-first century. Nature
460, 208-212. doi:10.1038/460208a
Hartung, T. and Hoffmann, S. (2009). Food for thought ... on in silico
methodsintoxicology.ALTEX26,155-166.doi:10.14573/altex.2009.
3.155
Hartung, T., Blaauboer, B. and Leist, M. (2009). Food for thought …
on education in alternative methods in toxicology. ALTEX 26, 255263. doi:10.14573/altex.2009.4.255

ALTEX 36(3), 2019

Herrmann et al.

Hartung, T. (2010). Comparative analysis of the revised Directive
2010/6106/EU for the protection of laboratory animals with its
predecessor 86/609/EEEEC – A t4 report. ALTEX 27, 285-303.
doi:10.14573/altex.2010.4.285
Hartung, T. (2013). Food for thought … Look back in anger – What
clinical studies tell us about preclinical work. ALTEX 30, 275-291.
doi:10.14573/altex.2013.3.275
Hartung, T. (2016). Making big sense from big data in toxicology by
read-across. ALTEX 33, 83-93. doi:10.14573/altex.1603091
Hartung, T. (2018). Making big sense from big data. Frontiers In Big
Data 1, 5. doi:10.3389/fdata.2018.00005
Harrison, R. K. (2016). Phase II and phase III failures: 2013-2015.
Nat Rev Drug Discov 15, 817-818. doi:10.1038/nrd.2016.184
Herrmann, K. (2019a). Refinement on the way towards replacement:
Are we doing what we can? In K. Herrmann and K. Jayne (eds.),
Animal Experimentation: Working Towards a Paradigm Change
(3-64). Vol. 22. Leiden, The Netherlands: Brill. doi:10.1163/
9789004391192_002
Herrmann, K. (2019b). Teaching animal-free approaches in basic
and applied biomedical research. Poster Presentation at JRC
Summer School on Non-Animal Approaches in Science. 21-14
May 2019, Ispra, Italy.
Herrmann, K. and Jayne, K. (2019). Animal Experimentation:
Working Towards a Paradigm Change. Vol. 22. Leiden, The
Netherlands: Brill. doi:10.1163/9789004391192
Holley, T., Bowe, G., Campia, I. et al. (2016). Accelerating progress in the replacement, reduction and refinement of animal
testing through better knowledge sharing. Publications Office
of the European Union. doi:10.2788/934083
Home Office (2018). Additional statistics on breeding and genotyping of animals for scientific procedures, Great Britain 2017
Home Office. https://bit.ly/2PGvzSf
Huh, D., Matthews, B. D., Mammoto, A. et al. (2010). Reconstituting organ-level lung functions on a chip. Science 328, 16621668. doi:10.1126/science.1188302
ICH (2009). Guidance on Non-Clinical Safety Studies for the
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. M3(R2) May 27, 2019. https://www.
ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
Jones, J. M. (2017). Americans hold record liberal views on most
moral issues. Gallup Poll Social Series. https://bit.ly/32iYlLe
Knight, A. (2008). 127 million non-human vertebrates used
worldwide for scientific purposes in 2005. Altern Lab Anim 36,
494-496.
Knight, A. (2019). Critically evaluating animal research. In K. Herrmann and K. Jayne (eds.), Animal Experimentation: Working Towards a Paradigm Change (321-340). Vol. 22. Leiden, The Netherlands: Brill. doi:10.1163/9789004391192_015
Kramer, L. A. and Greek, R. (2018). Human stakeholders and the
use of animals in drug development. Business and Society Review
123, 3-58.
Langley, G. R. (2014). Considering a new paradigm for Alzheimer’s
disease research. Drug Discov Today 19, 1114-1124. doi:10.1016/j.
drudis.2014.03.013
Langley, G., Austin, C. P., Balapure, A. K. et al. (2015). Lessons

ALTEX 36(3), 2019

from toxicology: Developing a 21st-century paradigm for medical
research. Environ Health Perspect 123, A268-272. doi:10.1289/
ehp.1510345
Langley, G. R., Adcock, I. M., Busquet, F. et al. (2017). Towards a
21st-century roadmap for biomedical research and drug discovery:
Consensus report and recommendations. Drug Discov Today 22,
327-339. doi:10.1016/j.drudis.2016.10.011
Leung, V., Rousseau-Blass, F., Beauchamp, G. et al. (2018). ARRIVE
has not arrived: Support for the ARRIVE (animal research: Reporting of in vivo experiments) guidelines does not improve the
reporting quality of papers in animal welfare, analgesia or anesthesia. PLoS One 13, e0197882. doi:10.1371/journal.pone.0197882
Luechtefeld, T., Rowlands, C. and Hartung, T. (2018). Big-data
and machine learning to revamp computational toxicology and
its use in risk assessment. Toxicol Res 7, 732-744. doi:10.1039/
C8TX00051D
Marshall, L. J. and Willett, C. (2018). Parkinson’s disease research:
Adopting a more human perspective to accelerate advances. Drug
Discov Today 23, 1950-1961. doi:10.1016/j.drudis.2018.09.010
Marshall, L. J., Austin, C. P., Casey, W. et al. (2018). Recommendations toward a human pathway-based approach to disease research.
Drug Discov Today 23, 1824-1832. doi:10.1016/j.drudis.2018.
05.038
Marx, U., Walles, H., Hoffmann, S. et al. (2012). ‘Human-on-achip’ developments: A translational cutting-edge alternative to
systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257.
doi:10.1177/026119291204000504
Marx, U., Andersson, T. B., Bahinski, A. et al. (2016). Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 33, 272321. doi:10.14573/altex.1603161
McNeish, J., Gardner, J. P., Wainger, B. J. et al. (2015). From dish to
bedside: Lessons learned while translating findings from a stem
cell model of disease to a clinical trial. Cell Stem Cell 17, 8-10.
doi:10.1016/j.stem.2015.06.013
Meigs, L., Smirnova, L., Rovida, C. et al. (2018). Animal testing and
its alternatives – The most important omics is economics. ALTEX
35, 275-305. doi:10.14573/altex.1807041
Mullard, A. (2015). Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov 14, 589-591. doi:10.1038/
nrd4708
Netherlands National Committee for the protection of animals used
for scientific purposes (NCad) (2016). Transition to non-animal
research. The Hague. https://www.ncadierproevenbeleid.nl/
documenten/rapport/2016/12/15/ncad-opinion-transition-to-nonanimal-research
Noor, F. (2019). The changing paradigm in preclinical toxicology:
In vitro and in silico methods in liver toxicity evaluations. In K.
Herrmann and K. Jayne (eds.), Animal Experimentation: Working Towards a Paradigm Change (610-638). Vol. 22. Leiden, The
Netherlands: Brill. doi:10.1163/9789004391192_026
NRC (2007). Toxicity Testing in the 21st Century. A Vision and a
Strategy. Washington, DC, USA: The National Academies Press.
doi:10.17226/11970
Ormandy, E. H., Schuppli, C. A. and Weary, D. M. (2009). Worldwide

351

Herrmann et al.

trends in the use of animals in research: The contribution of genetically-modified animal models. Altern Lab Anim 37, 63-68. doi:
10.1177/026119290903700109
Park, J., Lee, B. K., Jeong, G. S. et al. (2015). Three-dimensional
brain-on-a-chip with an interstitial level of flow and its application
as an in vitro model of Alzheimer’s disease. Lab Chip 15, 141-150.
doi:10.1039/c4lc00962b
Pippin, J. J. (2012). Animal research in medical sciences: Seeking
a convergence of science, medicine, and animal law. South Texas
Law Review 54, 469-511. http://faculty.smu.edu/jkazez/ar13/pippin.
pdf
Pistollato, F., Cavanaugh, S. E. and Chandrasekera, P. C. (2015). A
human-based integrated framework for Alzheimer’s disease research. J Alzheimers Dis 47, 857-868. doi:10.3233/JAD-150281
Pistollato, F., Ohayon, E. L., Lam, A. et al. (2016). Alzheimer disease research in the 21st century: Past and current failures, new
perspectives and funding priorities. Oncotarget 7, 38999-39016.
doi:10.18632/oncotarget.9175
Pound, P., Ebrahim, S., Sandercock, P. et al. (2004). Where is the evidence that animal research benefits humans? BMJ 328, 514-517.
doi:10.1136/bmj.328.7438.514
Pound, P. and Bracken, M. B. (2014). Is animal research sufficiently
evidence based to be a cornerstone of biomedical research? BMJ
348, g3387.doi:10.1136/bmj.g3387
Pound, P. and Ritskes-Hoitinga, M. (2018). Is it possible to overcome issues of external validity in preclinical animal research?
Why most animal models are bound to fail. J Transl Med 16, 304.
doi:10.1186/s12967-018-1678-1
Reardon, S. (2018). Alzheimer’s researchers seek better mice. Nature 563, 611-612. doi:10.1038/d41586-018-07484-w
Russell, W. M. S. and Burch, R. L. (1959). The Principles of Humane
Experimental Technique. https://books.google.it/books/about/The_
principles_of_humane_experimental_te.html?id=j75qAAAA
MAAJ&redir_esc=y
Savoji, H., Mohammadi, M. H., Rafatian, N. et al. (2019). Cardiovascular disease models: A game changing paradigm in drug discovery and screening. Biomaterials 198, 3-26. doi:10.1016/j.
biomaterials.2018.09.036
Skardal, A., Shupe, T. and Atala, A. (2016). Organoid-on-a-chip
and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today 21, 1399-1411. doi:10.1016/j.drudis.
2016.07.003
Stephens, M. L. (2012). Pursuing Medawar’s challenge for full replacement. ALTEX Proc 1, 23-26. http://www.altex.ch/resources/
023026_Stephens131.pdf

352

Stephens, M. and Mak, N. (2013). History of the 3Rs in toxicity testing: From Russell and Burch to 21st century toxicology. In D. G. Allen and M. D. Waters (eds.), Reducing, Refining and Replacing the
Use of Animals in Toxicity Testing. The Royal Society of Chemistry.
https://pubs.rsc.org/en/content/chapter/bk9781849736527-00001/
978-1-84973-652-7
Sutherland, B. A., Minnerup, J., Balami, J. S. et al. (2012). Neuroprotection for ischaemic stroke: Translation from the bench to the
bedside. Int J Stroke 7, 407-418. doi:10.1111/j.1747-4949.2012.
00770.x
Taylor, K. and Rego Alvarez, L. (2019). A summary of eu national
statistical reports of animal experiments in 2014-2016. ALTEX 36,
314-319. doi:10.14573/altex.1812211
Thomas, D. W., Burns, J., Audette, J. et al. (2016). Clinical development success rates 2006-2015. https://www.bio.org/sites/default/
files/Clinical%20Development%20Success%20Rates%2020062015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.
pdf
van Vliet, E., Daneshian, M., Beilmann et al. (2014). Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31, 479-493. doi:10.14573/
altex.1405271
van der Worp, H. B., Howells, D. W., Sena, E. S. et al. (2010). Can
animal models of disease reliably inform human studies? PLoS
Med 7, e1000245. doi:10.1371/journal.pmed.1000245
Vaudano, E., Vannieuwenhuyse, B., Van Der Geyten, S. et al.
(2015). Boosting translational research on Alzheimer’s disease in Europe: The innovative medicine initiative ad research
platform. Alzheimers Dement 11, 1121-1122. doi:10.1016/j.
jalz.2015.02.002
Wang, S. V., Verpillat, P., Rassen, J. A. et al. (2016). Transparency and reproducibility of observational cohort studies using
large healthcare databases. Clin Pharmacol Ther 99, 325-332.
doi:10.1002/cpt.329
Wilkinson, M. (2019). The potential of organ on chip technology for replacing animal testing. In K. Herrmann and K. Jayne
(eds.), Animal Experimentation: Working Towards a Paradigm
Change (639-653). Vol. 22. Leiden, The Netherlands: Brill. doi:
10.1163/9789004391192_027

Conflict of interest
The authors declare that they have no conflicts of interest.

ALTEX 36(3), 2019

